Psoriatic Arthritis
Conference Coverage
Secukinumab provides clinical benefit in phase 3 juvenile arthritis trial
Phase 3 trial shows secukinumab is effective for enthesitis-related arthritis and juvenile psoriatic arthritis in children.
Conference Coverage
Risankizumab shows efficacy, tolerability in patients with PsA
More than half of participants receiving risankizumab achieved the primary endpoint of at least 20% improvement in ACR response criteria, compared...
Conference Coverage
GRAPPA refines recommendations on psoriatic disease treatment
Biosimilars, Janus kinase inhibitors, and interleukin-23 inhibitors will feature in the 2021 update.
News
Lower SARS-CoV-2 vaccine responses seen in patients with immune-mediated inflammatory diseases
Patients who take methotrexate or rituximab seem to be especially vulnerable.
News
Trial: Fecal transplantation safe but ineffective in PsA
A trial found fecal microbiota transplantation in psoriatic arthritis inferior to sham but safe, and investigators said it’s worthy of future...
Conference Coverage
Multiple studies highlight pandemic’s impact on patients with rheumatic disease
From the Europe-based REUMAVID study to the United Kingdom’s CONTAIN study, some common themes are emerging, with lessons to be learned for future...
Conference Coverage
Psoriasis associated with an increased risk of COVID-19 in real-world study
Those treated with TNF-alpha inhibitors, methotrexate, and apremilast had statistically lower risks of COVID-19 vs. those on topical therapy.
Conference Coverage
Debate: Should biologics be used for milder cases of psoriasis?
The decision to use a biologic should hinge on how badly patients and their quality of life are affected, Dr. Langley said.
News
Boosting the presence of darker skin in rheumatology education
Doctors are beginning to address educational gaps in rheumatologists’ exposure to rheumatic and musculoskeletal diseases in people with darker...
News
Most patients with chronic inflammatory diseases have sufficient response to COVID-19 vaccination
A preprint publication of a study of 133 people with chronic inflammatory disease and 53 controls shows that those with CID mount immune responses...